Literature DB >> 15105147

Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver.

Chin-Chung Lin1, David Lourenco, Guifen Xu, Li-Tain Yeh.   

Abstract

The disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin were compared in rat and monkey red blood cells and liver. Our data reveal that the total ribavirin-related components (ribavirin plus its mono-, di-, and triphosphate metabolites) may account for most of the drug in monkey liver following prolonged oral administration of viramidine.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15105147      PMCID： PMC400578          DOI： 10.1128/AAC.48.5.1872-1875.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells.

Authors:  T P Zimmerman; R D Deeprose
Journal:  Biochem Pharmacol       Date:  1978-03-01       Impact factor: 5.858

2.  Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line.

Authors:  R C Willis; D A Carson; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

3.  The relationship between the metabolism of ribavirin and its proposed mechanism of action.

Authors:  J P Miller; L J Kigwana; D G Streeter; R K Robins; L N Simon; J Roboz
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

4.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

5.  Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys.

Authors:  E A Ferrara; J S Oishi; R W Wannemacher; E L Stephen
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

6.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

7.  Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys.

Authors:  Chin-Chung Lin; Kenneth Luu; David Lourenco; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

8.  Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions.

Authors:  Jim Zhen Wu; Heli Walker; Johnson Y N Lau; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Effects of ribavirin on red blood cells.

Authors:  P G Canonico; M D Kastello; C T Spears; J R Brown; E A Jackson; D E Jenkins
Journal:  Toxicol Appl Pharmacol       Date:  1984-06-30       Impact factor: 4.219

10.  Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals.

Authors:  Chin-chung Lin; Li-Tain Yeh; Domenico Vitarella; Zhi Hong
Journal:  Antivir Chem Chemother       Date:  2003-05
View more
  6 in total

Review 1.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.

Authors:  Jim Zhen Wu; Gary Larson; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Absorption, metabolism, and excretion of [14C]viramidine in humans.

Authors:  Chin-Chung Lin; Christine Xu; Nanqun Zhu; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes.

Authors:  Jim Zhen Wu; Gary Larson; Heli Walker; Jae Hoon Shim; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.

Authors:  M Palmer; R Rubin; V Rustgi
Journal:  Aliment Pharmacol Ther       Date:  2012-06-19       Impact factor: 8.171

Review 6.  Development of antiviral therapy for severe acute respiratory syndrome.

Authors:  Jindrich Cinatl; Martin Michaelis; Gerold Hoever; Wolfgang Preiser; Hans Wilhelm Doerr
Journal:  Antiviral Res       Date:  2005-04-26       Impact factor: 5.970
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.